Skip to content

Drug Interaction With Genes in Parkinson's Disease

Drug Interaction With Genes in Parkinson's Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01564992
Acronym
DIGPD
Enrollment
600
Registered
2012-03-28
Start date
2009-05-31
Completion date
2019-07-31
Last updated
2018-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's disease, Pharmacogenetics, Genetics

Brief summary

This observational study aims at identifying gene modifiers of Parkinson Disease (PD) and of treatment response and adverse events of antiparkinsonian drugs. Six hundred PD patients will be followed annually for up to 5 years. A biological collection will be associated with a full clinical assessment of motor and non motor symptoms, medical and treatment history, environmental factors. The association between candidate gene polymorphisms and disease or treatment complications will be analyzed.

Detailed description

Title : Drug interaction with genes in Parkinson Disease Objective: To identify genes associated to disease and treatment complication and response. Number of subjects: 500 Study duration : 6 years Design: Prospective cohort with biological collection Primary objective: Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment. Secondary objectives: * Prevalence and incidence of disease or treatment complications * Clinical risk factor for disease or treatment complications * Biomarkers of disease progression, disease or treatment complications

Interventions

OTHERIdentification of genes

Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women, age \> 18. * Parkinson Disease according to UKPDSBB criteria * PD diagnosis \< 6 years * Informed consent

Exclusion criteria

\- Atypical parkinsonism

Design outcomes

Primary

MeasureTime frame
All complications of the disease or treatment5 years

Countries

France

Contacts

Primary ContactJean-Christophe Corvol, MD, PhD
+33 1 42 16 57 66

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026